Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
5771 | 1577 | 38.5 | 62% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
159 | 3 | MENOPAUSE//ISOFLAVONES//TAMOXIFEN | 61134 |
329 | 2 | TAMOXIFEN//ESTROGEN RECEPTOR//AROMATASE INHIBITORS | 18133 |
5771 | 1 | ANTIESTROGEN//ANTIESTROGEN BINDING SITES//AEBS | 1577 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | ANTIESTROGEN | authKW | 206884 | 5% | 14% | 78 |
2 | ANTIESTROGEN BINDING SITES | authKW | 154890 | 1% | 100% | 8 |
3 | AEBS | authKW | 137678 | 1% | 89% | 8 |
4 | DROLOXIFENE | authKW | 121618 | 1% | 37% | 17 |
5 | EM 800 | authKW | 99570 | 0% | 86% | 6 |
6 | TAMOXIFEN | authKW | 98500 | 9% | 3% | 148 |
7 | CYCLOPROPYL ANTIESTROGENS | authKW | 77445 | 0% | 100% | 4 |
8 | ANALOG II | authKW | 61954 | 0% | 80% | 4 |
9 | DENDROGENIN | authKW | 61954 | 0% | 80% | 4 |
10 | JC HEUSON CANCEROL MAMMAIRE | address | 61938 | 1% | 27% | 12 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Oncology | 8021 | 37% | 0% | 591 |
2 | Endocrinology & Metabolism | 6492 | 25% | 0% | 399 |
3 | Biochemistry & Molecular Biology | 968 | 24% | 0% | 377 |
4 | Chemistry, Medicinal | 494 | 6% | 0% | 94 |
5 | Pharmacology & Pharmacy | 460 | 12% | 0% | 195 |
6 | Cell Biology | 169 | 7% | 0% | 116 |
7 | Biophysics | 143 | 5% | 0% | 72 |
8 | CYTOLOGY & HISTOLOGY | 18 | 0% | 0% | 3 |
9 | Obstetrics & Gynecology | 11 | 2% | 0% | 26 |
10 | Pathology | 10 | 1% | 0% | 23 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JC HEUSON CANCEROL MAMMAIRE | 61938 | 1% | 27% | 12 |
2 | ALFRED G KNUDSON CHAIR CANC | 60500 | 0% | 63% | 5 |
3 | ENDOCRINOL CELLULAR COMMUN | 38722 | 0% | 100% | 2 |
4 | ENDOCRINOL METAB OSSEUX | 38722 | 0% | 100% | 2 |
5 | JC HEUSON CANC MAMMAIRE | 38722 | 0% | 100% | 2 |
6 | SERV HISTOL CYTOL EXPT | 37227 | 0% | 38% | 5 |
7 | EQUIPE METAB ONCOGENESE DIFFERENCIAT CELLULAIRE | 29039 | 0% | 50% | 3 |
8 | U148 UNITE ENDOCRINOL CELLULAIRE MOLEC | 25814 | 0% | 67% | 2 |
9 | TEAM STEROL METAB THER EUT INNOVAT ONCOL | 24890 | 0% | 43% | 3 |
10 | ANEXPLO US006 | 19361 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY | 58519 | 10% | 2% | 165 |
2 | CANCER RESEARCH | 9065 | 9% | 0% | 136 |
3 | BREAST CANCER RESEARCH AND TREATMENT | 7731 | 3% | 1% | 54 |
4 | EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 6911 | 2% | 1% | 26 |
5 | ENDOCRINOLOGY | 4074 | 5% | 0% | 73 |
6 | MOLECULAR AND CELLULAR ENDOCRINOLOGY | 3011 | 2% | 0% | 37 |
7 | JOURNAL OF RECEPTOR RESEARCH | 2682 | 1% | 2% | 9 |
8 | BIOCHEMICAL PHARMACOLOGY | 2444 | 3% | 0% | 49 |
9 | ANTICANCER RESEARCH | 1724 | 3% | 0% | 42 |
10 | ENDOCRINE-RELATED CANCER | 1665 | 1% | 1% | 12 |
Author Key Words |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ANTIESTROGEN | 206884 | 5% | 14% | 78 | Search ANTIESTROGEN | Search ANTIESTROGEN |
2 | ANTIESTROGEN BINDING SITES | 154890 | 1% | 100% | 8 | Search ANTIESTROGEN+BINDING+SITES | Search ANTIESTROGEN+BINDING+SITES |
3 | AEBS | 137678 | 1% | 89% | 8 | Search AEBS | Search AEBS |
4 | DROLOXIFENE | 121618 | 1% | 37% | 17 | Search DROLOXIFENE | Search DROLOXIFENE |
5 | EM 800 | 99570 | 0% | 86% | 6 | Search EM+800 | Search EM+800 |
6 | TAMOXIFEN | 98500 | 9% | 3% | 148 | Search TAMOXIFEN | Search TAMOXIFEN |
7 | CYCLOPROPYL ANTIESTROGENS | 77445 | 0% | 100% | 4 | Search CYCLOPROPYL+ANTIESTROGENS | Search CYCLOPROPYL+ANTIESTROGENS |
8 | ANALOG II | 61954 | 0% | 80% | 4 | Search ANALOG+II | Search ANALOG+II |
9 | DENDROGENIN | 61954 | 0% | 80% | 4 | Search DENDROGENIN | Search DENDROGENIN |
10 | ANTIESTROGEN DRUG | 58084 | 0% | 100% | 3 | Search ANTIESTROGEN+DRUG | Search ANTIESTROGEN+DRUG |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | JORDAN, VC , (2015) THE NEW BIOLOGY OF ESTROGEN-INDUCED APOPTOSIS APPLIED TO TREAT AND PREVENT BREAST CANCER.ENDOCRINE-RELATED CANCER. VOL. 22. ISSUE 1. P. R1 -R31 | 76 | 51% | 15 |
2 | JORDAN, VC , MURPHY, CS , (1990) ENDOCRINE PHARMACOLOGY OF ANTIESTROGENS AS ANTITUMOR AGENTS.ENDOCRINE REVIEWS. VOL. 11. ISSUE 4. P. 578-610 | 140 | 46% | 361 |
3 | MACGREGOR, JI , JORDAN, VC , (1998) BASIC GUIDE TO THE MECHANISMS OF ANTIESTROGEN ACTION.PHARMACOLOGICAL REVIEWS. VOL. 50. ISSUE 2. P. 151 -196 | 118 | 27% | 497 |
4 | FAN, P , MAXIMOV, PY , CURPAN, RF , ABDERRAHMAN, B , JORDAN, VC , (2015) THE MOLECULAR, CELLULAR AND CLINICAL CONSEQUENCES OF TARGETING THE ESTROGEN RECEPTOR FOLLOWING ESTROGEN DEPRIVATION THERAPY.MOLECULAR AND CELLULAR ENDOCRINOLOGY. VOL. 418. ISSUE . P. 245 -263 | 73 | 39% | 4 |
5 | JORDAN, VC , (1984) BIOCHEMICAL PHARMACOLOGY OF ANTIESTROGEN ACTION.PHARMACOLOGICAL REVIEWS. VOL. 36. ISSUE 4. P. 245-276 | 83 | 64% | 389 |
6 | FAN, P , JORDAN, VC , (2014) ACQUIRED RESISTANCE TO SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMS) IN CLINICAL PRACTICE (TAMOXIFEN & RALOXIFENE) BY SELECTION PRESSURE IN BREAST CANCER CELL POPULATIONS.STEROIDS. VOL. 90. ISSUE . P. 44 -52 | 46 | 51% | 4 |
7 | PASQUALINI, JR , SUMIDA, C , GIAMBIAGI, N , (1988) PHARMACODYNAMIC AND BIOLOGICAL EFFECTS OF ANTI-ESTROGENS IN DIFFERENT MODELS.JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY. VOL. 31. ISSUE 4B. P. 613-643 | 79 | 64% | 76 |
8 | JORDAN, VC , FAN, P , ABDERRAHMAN, B , MAXIMOV, PY , HAWSAWI, YM , BHATTACHARYA, P , POKHAREL, N , (2016) SEX STEROID INDUCED APOPTOSIS AS A RATIONAL STRATEGY TO TREAT ANTI-HORMONE RESISTANT BREAST AND PROSTATE CANCER.DISCOVERY MEDICINE. VOL. 21. ISSUE 117. P. 411 -427 | 42 | 48% | 0 |
9 | SILVENTE-POIROT, S , DE MEDINA, P , RECORD, M , POIROT, M , (2016) FROM TAMOXIFEN TO DENDROGENIN A: THE DISCOVERY OF A MAMMALIAN TUMOR SUPPRESSOR AND CHOLESTEROL METABOLITE.BIOCHIMIE. VOL. 130. ISSUE . P. 109 -114 | 28 | 67% | 0 |
10 | JORDAN, VC , (2015) PROVEN VALUE OF TRANSLATIONAL RESEARCH WITH APPROPRIATE ANIMAL MODELS TO ADVANCE BREAST CANCER TREATMENT AND SAVE LIVES: THE TAMOXIFEN TALE.BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. VOL. 79. ISSUE 2. P. 254 -267 | 32 | 58% | 0 |
Classes with closest relation at Level 1 |